Pure form Sealed in dry, under -80°C
In solvent -20°C:3-6个月-80°C:24个月
[1]Schwartz S, Patel N, Longmire T, Jayaraman P, Jiang X, Lu H, Baker L, Velez J, Ramesh R, Wavreille AS, Verneret M, Fan H, Hu T, Xu F, Taraszka J, Pelletier M, Miyashiro J, Rinne M, Dranoff G, Sabatos-Peyton C, Cremasco V. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunother Adv. 2022 Aug 10;2(1):ltac019. doi: 10.1093/immadv/ltac019. Erratum in: Immunother Adv. 2023 Feb 18;3(1):ltad002. PMID: 36196369; PMCID: PMC9525012.